跳转至内容
Merck
CN

SML1385

Sigma-Aldrich

Lomitapide

≥98% (HPLC)

别名:

AEGR-733, BMS-201038, N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C39H37F6N3O2
分子量:
693.72
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 20 mg/mL, clear

储存温度

2-8°C

SMILES字符串

O=C(NCC(F)(F)F)C1(C(C=CC=C2)=C2C3=C1C=CC=C3)CCCCN(CC4)CCC4NC(C5=C(C6=CC=C(C(F)(F)F)C=C6)C=CC=C5)=O

InChI

1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)

InChI key

MBBCVAKAJPKAKM-UHFFFAOYSA-N

基因信息

应用

Lomitapide has been used as a microsomal triglyceride transfer protein (MTP) inhibitor to study its effects on very-low-density lipoproteins (VLDL) export in mouse hepatocytes.

生化/生理作用

Lomitapide can lower the secretion of very-low-density lipoproteins (VLDL) and chylomicrons.
Lomitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).
Lomitapide is an inhibitor of microsomal triglyceride transfer protein (MTP). Lomitapide has been shown to be highly effective in reducing LDL-cholesterol and triglycerides, and has been aproved for treatment of homozygous familial hypercholesterolemia.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly
Simon J, et al.
Cell Metabolism, 31(3), 605-622 (2020)
Frank M Sacks et al.
JAMA internal medicine, 174(3), 443-447 (2013-12-25)
Recurrent pancreatitis is a potentially fatal complication of severe hypertriglyceridemia. Genetic defects and lifestyle risk factors may render this condition unresponsive to current treatments. We report this first case of long-term management of intractable near-fatal recurrent pancreatitis secondary to severe
Severe hypertriglyceridemia with pancreatitis: thirteen years? treatment with lomitapide
Sacks F M, et al.
JAMA Internal Medicine, 174(3), 443-447 (2014)
Jorge Simon et al.
Cell metabolism, 31(3), 605-622 (2020-02-23)
Non-alcoholic steatohepatitis (NASH) is characterized by the accumulation of hepatic fat in an inflammatory/fibrotic background. Herein, we show that the hepatic high-activity glutaminase 1 isoform (GLS1) is overexpressed in NASH. Importantly, GLS1 inhibition reduces lipid content in choline and/or methionine

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门